Global Prescription Dermatology Therapeutics Market

Prescription Dermatology Therapeutics Comprehensive Study by Type (Topical Corticosteroids, Retinoids, Biologics, Calcineurin Inhibitors, Antihistamines, Hormone Therapy), Application (Psoriasis, Atopic Dermatitis, Acne, Rosacea, Skin Cancer, Scar), Drug Type (Humira, Remicade, Otezla, Stelara, Enbrel, Cosentyx, Neoral, Taltz, Cubicin, Canesten, Zyvox, Dupixent, Protopic, Valtrex, Eucrisa), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies), End User (Hospitals, Clinics, Cosmetic Centers, At-Home) Players and Region - Global Market Outlook to 2026

Prescription Dermatology Therapeutics Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Prescription Dermatology Therapeutics Market Scope?
Skin diseases are among the leading causes of the non-fatal burden of disease worldwide. Aging, trauma, and environmental and genetic factors can all lead to skin conditions. According to the World Health Organization (WHO), skin diseases, which are among the most common diseases affecting human health, affect nearly 900 million people worldwide at one point in time. Some of the most commonly reported skin conditions worldwide are pyoderma, scabies, acne, eczema, and warts. Acne is one of the most common skin conditions present in the United States that is affecting around 50 million Americans annually. According to the National Eczema Association, 31.6 million people in the US had some form of eczema in 2019. Therefore, it is expected that associated drugs will be in high demand in the coming years due to the increasing number of dermatological cases. As disposable income has increased, healthcare spending has increased over time. According to the Organization for Economic Co-operation and Development (OECD), the US recorded a 2.3% increase in disposable income in 2017 compared to the previous year. In addition, the OECD reported that around 3% of total health expenditure in Germany was spent on skin diseases in 2016. As people become aware of various skin diseases, they spend a significant portion of their income on dermatology and related services, which has fueled the growth of the dermatology drug market.

The Prescription Dermatology Therapeutics market study is being classified by Type (Topical Corticosteroids, Retinoids, Biologics, Calcineurin Inhibitors, Antihistamines and Hormone Therapy), by Application (Psoriasis, Atopic Dermatitis, Acne, Rosacea, Skin Cancer and Scar) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from European and United States will contribute to the maximum growth of Global Prescription Dermatology Therapeutics market throughout the predicted period.

Allergan Inc. (Ireland), Pfizer Inc. (United States), Aclaris Therapeutics Inc. (United States), Eli Lilly and Company (United States), Celgene Corporation (United States), Janssen Biotech Inc. (United States), Sonoma Pharmaceuticals (United States), Amgen Inc. (United States), LEO Pharma A/S (Denmark), NovaBay Pharmaceuticals, Inc. (United States), Bausch Health Companies Inc. (Canada), Novartis (Switzerland) and Sun Pharmaceuticals Ltd. (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Aurobindo Pharma Ltd. (India) and Lupin Limited (India).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Prescription Dermatology Therapeutics market by Type, Application and Region.

On the basis of geography, the market of Prescription Dermatology Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

In May 2020, Sanofi S.A. had thereby received USFDA approval of Dupixent (dupilumab) for the treatment of moderate to severe atopic dermatitis. and In April 2020, Bausch Health Companies Inc. and its dermatology company Ortho Dermatologics had received USFDA approval for the topical solution JUBLIA (efinaconazole) for the treatment of onychomycosis.


Influencing Market Trend
  • Increasing the Demand for This Drug for the Treatment of Mild-To-Moderate Atopic Dermatitis in Children and Adults
  • Increasing Preference for Consultation with Dermatologists for Chronic Skin Conditions
  • The Availability of a Broad Range of Prescription Drugs

Market Drivers
  • The Increasing Aging Population
  • Rising Incidence of Skin Diseases
  • Growing Awareness about Skin Diseases
  • The Growing Pollution and Ozone Layer Depletion Rate
  • The Rising Number of Skin Cancer Cases

Opportunities
  • Escalating Disposable Income in Developing Countries
  • Surging Number of Research Programs

Restraints
  • High Cost of Biologic Drugs
  • Side Effects Associated With the Drugs and Treatment

Challenges
  • Lack of Access to Skin Care Treatments in the Under Developed Countries


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Prescription Dermatology Therapeutics, Venture Capitalists and Private Equity Firms and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Topical Corticosteroids
  • Retinoids
  • Biologics
  • Calcineurin Inhibitors
  • Antihistamines
  • Hormone Therapy
By Application
  • Psoriasis
  • Atopic Dermatitis
  • Acne
  • Rosacea
  • Skin Cancer
  • Scar
By Drug Type
  • Humira
  • Remicade
  • Otezla
  • Stelara
  • Enbrel
  • Cosentyx
  • Neoral
  • Taltz
  • Cubicin
  • Canesten
  • Zyvox
  • Dupixent
  • Protopic
  • Valtrex
  • Eucrisa

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail Order Pharmacies

By End User
  • Hospitals
  • Clinics
  • Cosmetic Centers
  • At-Home

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Increasing Aging Population
      • 3.2.2. Rising Incidence of Skin Diseases
      • 3.2.3. Growing Awareness about Skin Diseases
      • 3.2.4. The Growing Pollution and Ozone Layer Depletion Rate
      • 3.2.5. The Rising Number of Skin Cancer Cases
    • 3.3. Market Challenges
      • 3.3.1. Lack of Access to Skin Care Treatments in the Under Developed Countries
    • 3.4. Market Trends
      • 3.4.1. Increasing the Demand for This Drug for the Treatment of Mild-To-Moderate Atopic Dermatitis in Children and Adults
      • 3.4.2. Increasing Preference for Consultation with Dermatologists for Chronic Skin Conditions
      • 3.4.3. The Availability of a Broad Range of Prescription Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Prescription Dermatology Therapeutics, by Type, Application, Drug Type, Distribution Channel, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Prescription Dermatology Therapeutics (Value)
      • 5.2.1. Global Prescription Dermatology Therapeutics by: Type (Value)
        • 5.2.1.1. Topical Corticosteroids
        • 5.2.1.2. Retinoids
        • 5.2.1.3. Biologics
        • 5.2.1.4. Calcineurin Inhibitors
        • 5.2.1.5. Antihistamines
        • 5.2.1.6. Hormone Therapy
      • 5.2.2. Global Prescription Dermatology Therapeutics by: Application (Value)
        • 5.2.2.1. Psoriasis
        • 5.2.2.2. Atopic Dermatitis
        • 5.2.2.3. Acne
        • 5.2.2.4. Rosacea
        • 5.2.2.5. Skin Cancer
        • 5.2.2.6. Scar
      • 5.2.3. Global Prescription Dermatology Therapeutics by: Drug Type (Value)
        • 5.2.3.1. Humira
        • 5.2.3.2. Remicade
        • 5.2.3.3. Otezla
        • 5.2.3.4. Stelara
        • 5.2.3.5. Enbrel
        • 5.2.3.6. Cosentyx
        • 5.2.3.7. Neoral
        • 5.2.3.8. Taltz
        • 5.2.3.9. Cubicin
        • 5.2.3.10. Canesten
        • 5.2.3.11. Zyvox
        • 5.2.3.12. Dupixent
        • 5.2.3.13. Protopic
        • 5.2.3.14. Valtrex
        • 5.2.3.15. Eucrisa
      • 5.2.4. Global Prescription Dermatology Therapeutics by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Mail Order Pharmacies
      • 5.2.5. Global Prescription Dermatology Therapeutics by: End User (Value)
        • 5.2.5.1. Hospitals
        • 5.2.5.2. Clinics
        • 5.2.5.3. Cosmetic Centers
        • 5.2.5.4. At-Home
      • 5.2.6. Global Prescription Dermatology Therapeutics Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Prescription Dermatology Therapeutics (Price)
      • 5.3.1. Global Prescription Dermatology Therapeutics by: Type (Price)
  • 6. Prescription Dermatology Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan Inc. (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Aclaris Therapeutics Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly and Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Celgene Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Janssen Biotech Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sonoma Pharmaceuticals (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Amgen Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. LEO Pharma A/S (Denmark)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. NovaBay Pharmaceuticals, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Bausch Health Companies Inc. (Canada)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Novartis (Switzerland)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Sun Pharmaceuticals Ltd. (India)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Prescription Dermatology Therapeutics Sale, by Type, Application, Drug Type, Distribution Channel, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Prescription Dermatology Therapeutics (Value)
      • 7.2.1. Global Prescription Dermatology Therapeutics by: Type (Value)
        • 7.2.1.1. Topical Corticosteroids
        • 7.2.1.2. Retinoids
        • 7.2.1.3. Biologics
        • 7.2.1.4. Calcineurin Inhibitors
        • 7.2.1.5. Antihistamines
        • 7.2.1.6. Hormone Therapy
      • 7.2.2. Global Prescription Dermatology Therapeutics by: Application (Value)
        • 7.2.2.1. Psoriasis
        • 7.2.2.2. Atopic Dermatitis
        • 7.2.2.3. Acne
        • 7.2.2.4. Rosacea
        • 7.2.2.5. Skin Cancer
        • 7.2.2.6. Scar
      • 7.2.3. Global Prescription Dermatology Therapeutics by: Drug Type (Value)
        • 7.2.3.1. Humira
        • 7.2.3.2. Remicade
        • 7.2.3.3. Otezla
        • 7.2.3.4. Stelara
        • 7.2.3.5. Enbrel
        • 7.2.3.6. Cosentyx
        • 7.2.3.7. Neoral
        • 7.2.3.8. Taltz
        • 7.2.3.9. Cubicin
        • 7.2.3.10. Canesten
        • 7.2.3.11. Zyvox
        • 7.2.3.12. Dupixent
        • 7.2.3.13. Protopic
        • 7.2.3.14. Valtrex
        • 7.2.3.15. Eucrisa
      • 7.2.4. Global Prescription Dermatology Therapeutics by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Mail Order Pharmacies
      • 7.2.5. Global Prescription Dermatology Therapeutics by: End User (Value)
        • 7.2.5.1. Hospitals
        • 7.2.5.2. Clinics
        • 7.2.5.3. Cosmetic Centers
        • 7.2.5.4. At-Home
      • 7.2.6. Global Prescription Dermatology Therapeutics Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Prescription Dermatology Therapeutics (Price)
      • 7.3.1. Global Prescription Dermatology Therapeutics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Prescription Dermatology Therapeutics: by Type(USD Million)
  • Table 2. Prescription Dermatology Therapeutics Topical Corticosteroids , by Region USD Million (2015-2020)
  • Table 3. Prescription Dermatology Therapeutics Retinoids , by Region USD Million (2015-2020)
  • Table 4. Prescription Dermatology Therapeutics Biologics , by Region USD Million (2015-2020)
  • Table 5. Prescription Dermatology Therapeutics Calcineurin Inhibitors , by Region USD Million (2015-2020)
  • Table 6. Prescription Dermatology Therapeutics Antihistamines , by Region USD Million (2015-2020)
  • Table 7. Prescription Dermatology Therapeutics Hormone Therapy , by Region USD Million (2015-2020)
  • Table 8. Prescription Dermatology Therapeutics: by Application(USD Million)
  • Table 9. Prescription Dermatology Therapeutics Psoriasis , by Region USD Million (2015-2020)
  • Table 10. Prescription Dermatology Therapeutics Atopic Dermatitis , by Region USD Million (2015-2020)
  • Table 11. Prescription Dermatology Therapeutics Acne , by Region USD Million (2015-2020)
  • Table 12. Prescription Dermatology Therapeutics Rosacea , by Region USD Million (2015-2020)
  • Table 13. Prescription Dermatology Therapeutics Skin Cancer , by Region USD Million (2015-2020)
  • Table 14. Prescription Dermatology Therapeutics Scar , by Region USD Million (2015-2020)
  • Table 15. Prescription Dermatology Therapeutics: by Drug Type(USD Million)
  • Table 16. Prescription Dermatology Therapeutics Humira , by Region USD Million (2015-2020)
  • Table 17. Prescription Dermatology Therapeutics Remicade , by Region USD Million (2015-2020)
  • Table 18. Prescription Dermatology Therapeutics Otezla , by Region USD Million (2015-2020)
  • Table 19. Prescription Dermatology Therapeutics Stelara , by Region USD Million (2015-2020)
  • Table 20. Prescription Dermatology Therapeutics Enbrel , by Region USD Million (2015-2020)
  • Table 21. Prescription Dermatology Therapeutics Cosentyx , by Region USD Million (2015-2020)
  • Table 22. Prescription Dermatology Therapeutics Neoral , by Region USD Million (2015-2020)
  • Table 23. Prescription Dermatology Therapeutics Taltz , by Region USD Million (2015-2020)
  • Table 24. Prescription Dermatology Therapeutics Cubicin , by Region USD Million (2015-2020)
  • Table 25. Prescription Dermatology Therapeutics Canesten , by Region USD Million (2015-2020)
  • Table 26. Prescription Dermatology Therapeutics Zyvox , by Region USD Million (2015-2020)
  • Table 27. Prescription Dermatology Therapeutics Dupixent , by Region USD Million (2015-2020)
  • Table 28. Prescription Dermatology Therapeutics Protopic , by Region USD Million (2015-2020)
  • Table 29. Prescription Dermatology Therapeutics Valtrex , by Region USD Million (2015-2020)
  • Table 30. Prescription Dermatology Therapeutics Eucrisa , by Region USD Million (2015-2020)
  • Table 31. Prescription Dermatology Therapeutics: by Distribution Channel(USD Million)
  • Table 32. Prescription Dermatology Therapeutics Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 33. Prescription Dermatology Therapeutics Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 34. Prescription Dermatology Therapeutics Mail Order Pharmacies , by Region USD Million (2015-2020)
  • Table 35. Prescription Dermatology Therapeutics: by End User(USD Million)
  • Table 36. Prescription Dermatology Therapeutics Hospitals , by Region USD Million (2015-2020)
  • Table 37. Prescription Dermatology Therapeutics Clinics , by Region USD Million (2015-2020)
  • Table 38. Prescription Dermatology Therapeutics Cosmetic Centers , by Region USD Million (2015-2020)
  • Table 39. Prescription Dermatology Therapeutics At-Home , by Region USD Million (2015-2020)
  • Table 40. South America Prescription Dermatology Therapeutics, by Country USD Million (2015-2020)
  • Table 41. South America Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 42. South America Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 43. South America Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 44. South America Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 45. South America Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 46. Brazil Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 47. Brazil Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 48. Brazil Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 49. Brazil Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 50. Brazil Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 51. Argentina Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 52. Argentina Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 53. Argentina Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 54. Argentina Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 55. Argentina Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 56. Rest of South America Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 57. Rest of South America Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 58. Rest of South America Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 59. Rest of South America Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 60. Rest of South America Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 61. Asia Pacific Prescription Dermatology Therapeutics, by Country USD Million (2015-2020)
  • Table 62. Asia Pacific Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 63. Asia Pacific Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 64. Asia Pacific Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 65. Asia Pacific Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 66. Asia Pacific Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 67. China Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 68. China Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 69. China Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 70. China Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 71. China Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 72. Japan Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 73. Japan Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 74. Japan Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 75. Japan Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 76. Japan Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 77. India Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 78. India Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 79. India Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 80. India Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 81. India Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 82. South Korea Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 83. South Korea Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 84. South Korea Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 85. South Korea Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 86. South Korea Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 87. Taiwan Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 88. Taiwan Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 89. Taiwan Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 90. Taiwan Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 91. Taiwan Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 92. Australia Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 93. Australia Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 94. Australia Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 95. Australia Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 96. Australia Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 97. Rest of Asia-Pacific Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 98. Rest of Asia-Pacific Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 99. Rest of Asia-Pacific Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 100. Rest of Asia-Pacific Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 101. Rest of Asia-Pacific Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 102. Europe Prescription Dermatology Therapeutics, by Country USD Million (2015-2020)
  • Table 103. Europe Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 104. Europe Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 105. Europe Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 106. Europe Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 107. Europe Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 108. Germany Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 109. Germany Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 110. Germany Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 111. Germany Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 112. Germany Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 113. France Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 114. France Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 115. France Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 116. France Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 117. France Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 118. Italy Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 119. Italy Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 120. Italy Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 121. Italy Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 122. Italy Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 123. United Kingdom Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 124. United Kingdom Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 125. United Kingdom Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 126. United Kingdom Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 127. United Kingdom Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 128. Netherlands Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 129. Netherlands Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 130. Netherlands Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 131. Netherlands Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 132. Netherlands Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 133. Rest of Europe Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 134. Rest of Europe Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 135. Rest of Europe Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 136. Rest of Europe Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 137. Rest of Europe Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 138. MEA Prescription Dermatology Therapeutics, by Country USD Million (2015-2020)
  • Table 139. MEA Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 140. MEA Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 141. MEA Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 142. MEA Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 143. MEA Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 144. Middle East Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 145. Middle East Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 146. Middle East Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 147. Middle East Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 148. Middle East Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 149. Africa Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 150. Africa Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 151. Africa Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 152. Africa Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 153. Africa Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 154. North America Prescription Dermatology Therapeutics, by Country USD Million (2015-2020)
  • Table 155. North America Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 156. North America Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 157. North America Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 158. North America Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 159. North America Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 160. United States Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 161. United States Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 162. United States Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 163. United States Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 164. United States Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 165. Canada Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 166. Canada Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 167. Canada Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 168. Canada Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 169. Canada Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 170. Mexico Prescription Dermatology Therapeutics, by Type USD Million (2015-2020)
  • Table 171. Mexico Prescription Dermatology Therapeutics, by Application USD Million (2015-2020)
  • Table 172. Mexico Prescription Dermatology Therapeutics, by Drug Type USD Million (2015-2020)
  • Table 173. Mexico Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2015-2020)
  • Table 174. Mexico Prescription Dermatology Therapeutics, by End User USD Million (2015-2020)
  • Table 175. Prescription Dermatology Therapeutics: by Type(USD/Units)
  • Table 176. Company Basic Information, Sales Area and Its Competitors
  • Table 177. Company Basic Information, Sales Area and Its Competitors
  • Table 178. Company Basic Information, Sales Area and Its Competitors
  • Table 179. Company Basic Information, Sales Area and Its Competitors
  • Table 180. Company Basic Information, Sales Area and Its Competitors
  • Table 181. Company Basic Information, Sales Area and Its Competitors
  • Table 182. Company Basic Information, Sales Area and Its Competitors
  • Table 183. Company Basic Information, Sales Area and Its Competitors
  • Table 184. Company Basic Information, Sales Area and Its Competitors
  • Table 185. Company Basic Information, Sales Area and Its Competitors
  • Table 186. Company Basic Information, Sales Area and Its Competitors
  • Table 187. Company Basic Information, Sales Area and Its Competitors
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Prescription Dermatology Therapeutics: by Type(USD Million)
  • Table 190. Prescription Dermatology Therapeutics Topical Corticosteroids , by Region USD Million (2021-2026)
  • Table 191. Prescription Dermatology Therapeutics Retinoids , by Region USD Million (2021-2026)
  • Table 192. Prescription Dermatology Therapeutics Biologics , by Region USD Million (2021-2026)
  • Table 193. Prescription Dermatology Therapeutics Calcineurin Inhibitors , by Region USD Million (2021-2026)
  • Table 194. Prescription Dermatology Therapeutics Antihistamines , by Region USD Million (2021-2026)
  • Table 195. Prescription Dermatology Therapeutics Hormone Therapy , by Region USD Million (2021-2026)
  • Table 196. Prescription Dermatology Therapeutics: by Application(USD Million)
  • Table 197. Prescription Dermatology Therapeutics Psoriasis , by Region USD Million (2021-2026)
  • Table 198. Prescription Dermatology Therapeutics Atopic Dermatitis , by Region USD Million (2021-2026)
  • Table 199. Prescription Dermatology Therapeutics Acne , by Region USD Million (2021-2026)
  • Table 200. Prescription Dermatology Therapeutics Rosacea , by Region USD Million (2021-2026)
  • Table 201. Prescription Dermatology Therapeutics Skin Cancer , by Region USD Million (2021-2026)
  • Table 202. Prescription Dermatology Therapeutics Scar , by Region USD Million (2021-2026)
  • Table 203. Prescription Dermatology Therapeutics: by Drug Type(USD Million)
  • Table 204. Prescription Dermatology Therapeutics Humira , by Region USD Million (2021-2026)
  • Table 205. Prescription Dermatology Therapeutics Remicade , by Region USD Million (2021-2026)
  • Table 206. Prescription Dermatology Therapeutics Otezla , by Region USD Million (2021-2026)
  • Table 207. Prescription Dermatology Therapeutics Stelara , by Region USD Million (2021-2026)
  • Table 208. Prescription Dermatology Therapeutics Enbrel , by Region USD Million (2021-2026)
  • Table 209. Prescription Dermatology Therapeutics Cosentyx , by Region USD Million (2021-2026)
  • Table 210. Prescription Dermatology Therapeutics Neoral , by Region USD Million (2021-2026)
  • Table 211. Prescription Dermatology Therapeutics Taltz , by Region USD Million (2021-2026)
  • Table 212. Prescription Dermatology Therapeutics Cubicin , by Region USD Million (2021-2026)
  • Table 213. Prescription Dermatology Therapeutics Canesten , by Region USD Million (2021-2026)
  • Table 214. Prescription Dermatology Therapeutics Zyvox , by Region USD Million (2021-2026)
  • Table 215. Prescription Dermatology Therapeutics Dupixent , by Region USD Million (2021-2026)
  • Table 216. Prescription Dermatology Therapeutics Protopic , by Region USD Million (2021-2026)
  • Table 217. Prescription Dermatology Therapeutics Valtrex , by Region USD Million (2021-2026)
  • Table 218. Prescription Dermatology Therapeutics Eucrisa , by Region USD Million (2021-2026)
  • Table 219. Prescription Dermatology Therapeutics: by Distribution Channel(USD Million)
  • Table 220. Prescription Dermatology Therapeutics Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 221. Prescription Dermatology Therapeutics Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 222. Prescription Dermatology Therapeutics Mail Order Pharmacies , by Region USD Million (2021-2026)
  • Table 223. Prescription Dermatology Therapeutics: by End User(USD Million)
  • Table 224. Prescription Dermatology Therapeutics Hospitals , by Region USD Million (2021-2026)
  • Table 225. Prescription Dermatology Therapeutics Clinics , by Region USD Million (2021-2026)
  • Table 226. Prescription Dermatology Therapeutics Cosmetic Centers , by Region USD Million (2021-2026)
  • Table 227. Prescription Dermatology Therapeutics At-Home , by Region USD Million (2021-2026)
  • Table 228. South America Prescription Dermatology Therapeutics, by Country USD Million (2021-2026)
  • Table 229. South America Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 230. South America Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 231. South America Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 232. South America Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 233. South America Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 234. Brazil Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 235. Brazil Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 236. Brazil Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 237. Brazil Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 238. Brazil Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 239. Argentina Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 240. Argentina Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 241. Argentina Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 242. Argentina Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 243. Argentina Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 244. Rest of South America Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 245. Rest of South America Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 246. Rest of South America Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 247. Rest of South America Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 248. Rest of South America Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 249. Asia Pacific Prescription Dermatology Therapeutics, by Country USD Million (2021-2026)
  • Table 250. Asia Pacific Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 251. Asia Pacific Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 252. Asia Pacific Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 253. Asia Pacific Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 254. Asia Pacific Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 255. China Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 256. China Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 257. China Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 258. China Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 259. China Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 260. Japan Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 261. Japan Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 262. Japan Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 263. Japan Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 264. Japan Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 265. India Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 266. India Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 267. India Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 268. India Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 269. India Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 270. South Korea Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 271. South Korea Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 272. South Korea Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 273. South Korea Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 274. South Korea Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 275. Taiwan Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 276. Taiwan Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 277. Taiwan Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 278. Taiwan Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 279. Taiwan Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 280. Australia Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 281. Australia Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 282. Australia Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 283. Australia Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 284. Australia Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 285. Rest of Asia-Pacific Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 286. Rest of Asia-Pacific Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 287. Rest of Asia-Pacific Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 288. Rest of Asia-Pacific Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 289. Rest of Asia-Pacific Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 290. Europe Prescription Dermatology Therapeutics, by Country USD Million (2021-2026)
  • Table 291. Europe Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 292. Europe Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 293. Europe Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 294. Europe Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 295. Europe Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 296. Germany Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 297. Germany Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 298. Germany Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 299. Germany Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 300. Germany Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 301. France Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 302. France Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 303. France Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 304. France Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 305. France Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 306. Italy Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 307. Italy Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 308. Italy Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 309. Italy Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 310. Italy Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 311. United Kingdom Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 312. United Kingdom Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 313. United Kingdom Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 314. United Kingdom Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 315. United Kingdom Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 316. Netherlands Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 317. Netherlands Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 318. Netherlands Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 319. Netherlands Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 320. Netherlands Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 321. Rest of Europe Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 322. Rest of Europe Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 323. Rest of Europe Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 324. Rest of Europe Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 325. Rest of Europe Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 326. MEA Prescription Dermatology Therapeutics, by Country USD Million (2021-2026)
  • Table 327. MEA Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 328. MEA Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 329. MEA Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 330. MEA Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 331. MEA Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 332. Middle East Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 333. Middle East Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 334. Middle East Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 335. Middle East Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 336. Middle East Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 337. Africa Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 338. Africa Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 339. Africa Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 340. Africa Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 341. Africa Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 342. North America Prescription Dermatology Therapeutics, by Country USD Million (2021-2026)
  • Table 343. North America Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 344. North America Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 345. North America Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 346. North America Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 347. North America Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 348. United States Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 349. United States Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 350. United States Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 351. United States Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 352. United States Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 353. Canada Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 354. Canada Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 355. Canada Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 356. Canada Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 357. Canada Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 358. Mexico Prescription Dermatology Therapeutics, by Type USD Million (2021-2026)
  • Table 359. Mexico Prescription Dermatology Therapeutics, by Application USD Million (2021-2026)
  • Table 360. Mexico Prescription Dermatology Therapeutics, by Drug Type USD Million (2021-2026)
  • Table 361. Mexico Prescription Dermatology Therapeutics, by Distribution Channel USD Million (2021-2026)
  • Table 362. Mexico Prescription Dermatology Therapeutics, by End User USD Million (2021-2026)
  • Table 363. Prescription Dermatology Therapeutics: by Type(USD/Units)
  • Table 364. Research Programs/Design for This Report
  • Table 365. Key Data Information from Secondary Sources
  • Table 366. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Prescription Dermatology Therapeutics: by Type USD Million (2015-2020)
  • Figure 5. Global Prescription Dermatology Therapeutics: by Application USD Million (2015-2020)
  • Figure 6. Global Prescription Dermatology Therapeutics: by Drug Type USD Million (2015-2020)
  • Figure 7. Global Prescription Dermatology Therapeutics: by Distribution Channel USD Million (2015-2020)
  • Figure 8. Global Prescription Dermatology Therapeutics: by End User USD Million (2015-2020)
  • Figure 9. South America Prescription Dermatology Therapeutics Share (%), by Country
  • Figure 10. Asia Pacific Prescription Dermatology Therapeutics Share (%), by Country
  • Figure 11. Europe Prescription Dermatology Therapeutics Share (%), by Country
  • Figure 12. MEA Prescription Dermatology Therapeutics Share (%), by Country
  • Figure 13. North America Prescription Dermatology Therapeutics Share (%), by Country
  • Figure 14. Global Prescription Dermatology Therapeutics: by Type USD/Units (2015-2020)
  • Figure 15. Global Prescription Dermatology Therapeutics share by Players 2020 (%)
  • Figure 16. Global Prescription Dermatology Therapeutics share by Players (Top 3) 2020(%)
  • Figure 17. Global Prescription Dermatology Therapeutics share by Players (Top 5) 2020(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Allergan Inc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 20. Allergan Inc. (Ireland) Revenue: by Geography 2020
  • Figure 21. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 23. Aclaris Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Aclaris Therapeutics Inc. (United States) Revenue: by Geography 2020
  • Figure 25. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 27. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 28. Celgene Corporation (United States) Revenue: by Geography 2020
  • Figure 29. Janssen Biotech Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Janssen Biotech Inc. (United States) Revenue: by Geography 2020
  • Figure 31. Sonoma Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 32. Sonoma Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 33. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Amgen Inc. (United States) Revenue: by Geography 2020
  • Figure 35. LEO Pharma A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 36. LEO Pharma A/S (Denmark) Revenue: by Geography 2020
  • Figure 37. NovaBay Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. NovaBay Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 39. Bausch Health Companies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 40. Bausch Health Companies Inc. (Canada) Revenue: by Geography 2020
  • Figure 41. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 42. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 43. Sun Pharmaceuticals Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 44. Sun Pharmaceuticals Ltd. (India) Revenue: by Geography 2020
  • Figure 45. Global Prescription Dermatology Therapeutics: by Type USD Million (2021-2026)
  • Figure 46. Global Prescription Dermatology Therapeutics: by Application USD Million (2021-2026)
  • Figure 47. Global Prescription Dermatology Therapeutics: by Drug Type USD Million (2021-2026)
  • Figure 48. Global Prescription Dermatology Therapeutics: by Distribution Channel USD Million (2021-2026)
  • Figure 49. Global Prescription Dermatology Therapeutics: by End User USD Million (2021-2026)
  • Figure 50. South America Prescription Dermatology Therapeutics Share (%), by Country
  • Figure 51. Asia Pacific Prescription Dermatology Therapeutics Share (%), by Country
  • Figure 52. Europe Prescription Dermatology Therapeutics Share (%), by Country
  • Figure 53. MEA Prescription Dermatology Therapeutics Share (%), by Country
  • Figure 54. North America Prescription Dermatology Therapeutics Share (%), by Country
  • Figure 55. Global Prescription Dermatology Therapeutics: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Allergan Inc. (Ireland)
  • Pfizer Inc. (United States)
  • Aclaris Therapeutics Inc. (United States)
  • Eli Lilly and Company (United States)
  • Celgene Corporation (United States)
  • Janssen Biotech Inc. (United States)
  • Sonoma Pharmaceuticals (United States)
  • Amgen Inc. (United States)
  • LEO Pharma A/S (Denmark)
  • NovaBay Pharmaceuticals, Inc. (United States)
  • Bausch Health Companies Inc. (Canada)
  • Novartis (Switzerland)
  • Sun Pharmaceuticals Ltd. (India)
Additional players considered in the study are as follows:
Aurobindo Pharma Ltd. (India) , Lupin Limited (India)
Select User Access Type

Key Highlights of Report


May 2021 219 Pages 82 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Prescription Dermatology Therapeutics Market Quantitative research analysis
Global Prescription Dermatology Therapeutics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Prescription Dermatology Therapeutics market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Prescription Dermatology Therapeutics market are Allergan Inc. (Ireland), Pfizer Inc. (United States), Aclaris Therapeutics Inc. (United States), Eli Lilly and Company (United States), Celgene Corporation (United States), Janssen Biotech Inc. (United States), Sonoma Pharmaceuticals (United States), Amgen Inc. (United States), LEO Pharma A/S (Denmark), NovaBay Pharmaceuticals, Inc. (United States), Bausch Health Companies Inc. (Canada), Novartis (Switzerland) and Sun Pharmaceuticals Ltd. (India), to name a few.
In this highly competitive & fast evolving Prescription Dermatology Therapeutics industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Prescription Dermatology Therapeutics Market Report?

Have a Query? Click Here

Other Related Reports

Desensitization Comprehensive Study by Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy), Application (Allergic Rhinitis, Allergic Asthma, Other), End-users (Hospitals, Clinics, Others) Pla...
$ 3500
Tissue Regeneration Comprehensive Study by Application (Cardiovascular, Oncology, Dermatology, Orthopedic, Neurology, Ophthalmology, Others), Raw Material (Synthetic, Genetically Modified, Biological...
$ 3750
Dilated Cardiomyopathy Comprehensive Study by Drugs (Angiotensin-Converting Enzyme (ACE) Inhibitors, Beta Blockers, Aldosterone Antagonists, Digitalis, Angiotensin II Receptor Blockers, Anticoagulant...
$ 3750
Atherosclerosis Therapeutics Comprehensive Study by Application (Lipid Lowering, Anti-Platelets, Anti-Hypertensive, Other Therapeutics), End-users (Hospitals, Clinics, Others), Distribution Channel (...
$ 3650
Burn Therapy Comprehensive Study by Application (Medical Treatment, Physical Therapy, Surgical, Others), Depth of Burn (Minor, Partial Thickness, Full Thickness), End-Use (Hospitals, Clinics, Others)...
$ 3500
Abdominal Closure System Comprehensive Study by Type (Laparoscopic Abdominal Closure Systems Devices, Traction Systems), Application (Laparoscopic surgeries, Abdominal Trauma, After Transplantation S...
$ 3450